Esperion Therapeutics (ESPR) PT Raised to $130 at Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/30/2026
- Crude Inventory Fell 7.2 Million Barrels Last Week - EIA
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- Wall Street closes down sharply after Fed holds rates unchanged
- Grant Thornton Advisors to buy CBIZ in $5 billion deal, expand US accounting reach
- How will the S&P 500 react to today’s FOMC? JPM lays out the playbook
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports First Quarter 2015 Financial Results
May 7, 2015 4:06 PM EDTANN ARBOR, MI -- (Marketwired) -- 05/07/15 -- Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today provided ETC-1002 (bempedoic acid) development program updates and financial results for the first quarter ended March 31, 2015.
"Esperion had another truly transformational quarter," said Tim M. Mayleben, president and chief executive officer of Esperion. "Following the recently announced positive Phase 2b add-on to statin clinical study results of ETC-1002, we are actively... More
